by Jeremy Burt | Feb 20, 2024 | News
As the Society of Toxicology (SOT) Annual Meeting approaches, biopharmaceutical companies have a prime opportunity to engage with industry leaders and explore innovative solutions to advance drug development initiatives. This year, the team at Scantox extends a warm...
by Tina Andersen | Nov 30, 2023 | News
30th November 2023 — Today Scantox, together with its majority owner Impilo, has agreed to acquire the neuropharmacology division of QPS Austria GmbH (“QPS Neuro” or “the Company”) ultimately owned by QPS Holdings LLC. QPS Neuro is a leading drug discovery...
by Tina Andersen | Nov 20, 2023 | News, Blog
Scantox A/S (“Scantox”) announces the acquisition of Solural Pharma (“Solural”) in Denmark. Scantox is the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo. Solural has strong...
by Tina Andersen | Nov 8, 2023 | News
November 8th – Scantox Group, a leading provider of nonclinical services in Europe, has named Morten Fjordholt as Sr. Business Development Director with the overall responsibility of growing sales within toxicology and lab services and fostering positive relationships...
by Tina Andersen | Aug 31, 2023 | News
31 August 2023 — Scantox A/S (“Scantox” or the “Company”), the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo, is pleased to announce the acquisition of Q&Q Labs AB...
by Tina Andersen | Jul 7, 2023 | News
July 7th – Scantox Group, a leading provider of nonclinical services in Europe, has named Andy Brown as Group Chief Commercial Officer with the overall responsibility of growing sales within toxicology, discovery and lab services and fostering positive relationships...